for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Gilead Sciences, Inc.

GILD.O

Latest Trade

70.43USD

Change

-1.34(-1.87%)

Volume

8,987,261

Today's Range

70.07

 - 

71.52

52 Week Range

61.39

 - 

74.12

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
71.77
Open
71.42
Volume
8,987,261
3M AVG Volume
150.16
Today's High
71.52
Today's Low
70.07
52 Week High
74.12
52 Week Low
61.39
Shares Out (MIL)
1,254.38
Market Cap (MIL)
90,027.10
Forward P/E
8.88
Dividend (Yield %)
3.96

Next Event

Q4 2021 Gilead Sciences Inc Earnings Release

Latest Developments

更多

Gilead Announces Clinical Trial Collaborations With Merck

Gilead Sciences - Brett A. Pletcher Plans To Retire From Position As Executive Vice President, Corporate Affairs, General Counsel & Corporate Secretary

Merck Announces Clinical Holds On Studies Evaluating Islatravir

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.

Industry

Biotechnology & Drugs

Contact Info

333 LAKESIDE DR

FOSTER CITY, CA

94404

United States

+1.650.5743000

https://www.gilead.com/

Executive Leadership

Daniel O'Day

Chairman of the Board, Chief Executive Officer

Andrew D. Dickinson

Chief Financial Officer

Flavius Martin

Executive Vice President - Research

Johanna Mercier

Chief Commercial Officer

Merdad V. Parsey

Chief Medical Officer

Key Stats

2.48 mean rating - 31 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

22.1K

2019

22.4K

2020

24.7K

2021(E)

26.5K
EPS (USD)

2018

6.670

2019

6.630

2020

7.090

2021(E)

8.089
Price To Earnings (TTM)
12.28
Price To Sales (TTM)
3.28
Price To Book (MRQ)
4.20
Price To Cash Flow (TTM)
9.55
Total Debt To Equity (MRQ)
128.95
LT Debt To Equity (MRQ)
117.26
Return on Investment (TTM)
13.62
Return on Equity (TTM)
11.52

Latest News

Latest News

UPDATE 1-Gilead says counterfeit versions of its HIV drugs ended up with patients

Gilead Sciences Inc said an unauthorized network of drug distributors and suppliers sold pharmacies more than $250 million of counterfeit versions of its HIV treatments over the last two years, endangering patients.

UPDATE 1-Gilead withdraws use of Zydelig to treat two types of cancer

Gilead Sciences Inc on Friday notified the U.S. health regulator of its decision to voluntarily withdraw the use of its drug Zydelig for two types of cancer - follicular lymphoma and small lymphocytic leukemia.

Gilead withdraws use of Zydelig to treat two types of cancer

Gilead Sciences Inc has notified the U.S. health regulator of its decision to voluntarily withdraw the use of its drug Zydelig for two types of cancer - follicular lymphoma and small lymphocytic leukemia. (Reporting by Leroy Leo in Bengaluru; Editing by Arun Koyyur)

UPDATE 2-Gilead trims 2021 sales forecast for non-COVID products

Gilead Sciences Inc on Thursday posted higher-than-expected third-quarter earnings on strong demand for its COVID-19 antiviral treatment, but said 2021 sales of its other drugs will fall short of earlier estimates.

Gilead beats profit expectations on COVID-19 drug sales

Gilead Sciences Inc on Thursday posted higher-than-expected third-quarter earnings as strong demand for its COVID-19 antiviral treatment, Veklury, offset flagging sales of its HIV drugs.

CORRECTED-UPDATE 2-Gilead Sciences wins reversal of $1.2 bln award in patent case with Bristol Myers

A U.S. appeals court on Thursday threw out a $1.2 billion ruling against Gilead Sciences Inc, finding a patent on a cancer therapy it was accused of infringing was invalid, in a blow to rival Bristol Myers Squibb Co.

REFILE-Gilead Sciences wins reversal of $1.2 bln fine against Bristol Myers in patent case

Gilead Sciences Inc escaped a $1.2 billion fine, after the Federal Circuit Court of Appeals on Thursday found the relevant parts of a Bristol Myers Squibb patent that Gilead's Yescarta cancer drug allegedly infringed were invalid.

Gilead to require U.S. workers receive COVID-19 vaccine

Gilead Sciences Inc said on Monday it will require all its employees and contractors in the United States to become vaccinated against COVID-19.

Gilead says aware of counterfeit HIV medicines being distributed in U.S.

Gilead Sciences said on Thursday it has become aware that tampered and counterfeit versions of its HIV treatments, Biktarvy and Descovy, are in circulation within U.S. drug distribution networks.

UPDATE 2-Gilead's COVID-19 drug helps boost 2nd-quarter results as HIV sales dip

Gilead Sciences Inc on Thursday posted a higher-than-expected second-quarter profit, helped by strong demand for its COVID-19 antiviral treatment, Veklury, but sales of its flagship HIV drugs lagged as the pandemic continued to limit visits to doctors.

Strong COVID-19 drug sales help boost Gilead second-quarter results

Gilead Sciences Inc on Thursday posted higher second-quarter earnings, helped by strong sales of its COVID-19 antiviral treatment, Veklury, as well as hepatitis drugs.

U.S. FDA allows Lilly's COVID-19 drug to be taken without remdesivir

The U.S. health regulator expanded the emergency use authorization for Eli Lilly's COVID-19 drug baricitinib, saying it could now be used without taking Gilead's drug remdesivir along with it, Lilly said on Thursday.

UPDATE 1-Unauthorized COVID-19 drugs bound for Mexico seized by U.S. authorities - WSJ

Federal authorities have seized at U.S. airports unauthorized versions of the COVID-19 treatment remdesivir destined for distribution in Mexico, the Wall Street Journal reported on Wednesday.

Gilead's remdesivir reduces COVID-19 mortality risk- data

Gilead Sciences Inc said an analysis showed its antiviral remdesivir reduced mortality rates in hospitalized patients with COVID-19 and increased the likelihood of being discharged by day 28 after a five-day course of the treatment.

REFILE-UPDATE 1-EU regulator backs extending approval for remdesivir for another year

The European Medicines Agency (EMA) on Friday recommended extending conditional marketing approval by a year for Gilead Sciences' COVID-19 treatment, remdesivir, the only drug so far that has been authorized for use in the region.

UPDATE 1-Eli Lilly to supply 400,000 tablets of its COVID-19 treatment to India

Eli Lilly and Co said on Tuesday it would supply 400,000 tablets of its COVID-19 treatment, to be used with Gilead's remdesivir, to the Indian government as the country fights a raging pandemic that has morgues and hospitals overflowing.

UPDATE 2-Gilead HIV, hepatitis C sales dip, shares down 2.6%

Gilead Sciences Inc on Thursday reported first-quarter revenue that fell short of Wall Street estimates as the coronavirus pandemic hurt sales of its flagship HIV and hepatitis C drugs, partially offset by sales of COVID-19 antiviral treatment remdesivir.

Gilead 1st-quarter profit rises despite lower HIV drug sales

Gilead Sciences Inc on Thursday said its first-quarter product sales rose 16%, including $1.46 billion in sales of its COVID-19 antiviral drug remdesivir, but sales of flagship HIV and hepatitis C drugs were down due to the effects of the pandemic.

UPDATE 4-U.S. drugmakers step up supplies as India battles COVID-19 surge

U.S. drugmaker Merck & Co joined Gilead Sciences on Tuesday in lending support to India as the world's second-most populous country scrambles to address drug shortages and bring a raging new wave of COVID-19 cases under control.

Gilead to help India increase production of remdesivir

Gilead Sciences Inc said on Monday it will provide support to new local manufacturing facilities in India and donate active pharmaceutical ingredient to scale up production of its COVID-19 drug, remdesivir. (https://refini.tv/2QqfmCn) (Reporting by Trisha Roy in Bengaluru...

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up